Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

por Windyga, Jerzy, Stasyshyn, Oleksandra, Lissitchkov, Toshko, Mamonov, Vasily, Serban, Margit, Rusen, Luminita, Ploder, Bettina, Tangada, Srilatha
Publicado 2020

Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately sever...

por Pabinger, Ingrid, Mamonov, Vasily, Windyga, Jerzy, Engl, Werner, Doralt, Jennifer, Tangada, Srilatha, Spotts, Gerald, Ewenstein, Bruce
Publicado 2021

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

por Windyga, Jerzy, Timofeeva, Margarita, Stasyshyn, Oleksandra, Mamonov, Vasily, Lamas Castellanos, José Luis, Lissitchkov, Toshko, Chojnowski, Krzysztof, Chapman, Miranda, Pavlova, Borislava G., Tangada, Srilatha
Publicado 2020

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

por Pasi, K. John, Lissitchkov, Toshko, Mamonov, Vasily, Mant, Tim, Timofeeva, Margarita, Bagot, Catherine, Chowdary, Pratima, Georgiev, Pencho, Gercheva‐Kyuchukova, Liana, Madigan, Kate, Van Nguyen, Huy, Yu, Qifeng, Mei, Baisong, Benson, Craig C., Ragni, Margaret V.
Publicado 2021